Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on October 21, 2008
Japanese Journal of Clinical Oncology 2008 38(12):844-848; doi:10.1093/jjco/hyn107
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
38/12/844    most recent
hyn107v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ishidoya, S.
Right arrow Articles by Arai, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishidoya, S.
Right arrow Articles by Arai, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

The Outcome of Prostate Cancer Screening in a Normal Japanese Population with PSA of 2–4 ng/ml and the Free/Total PSA Under 12%

Shigeto Ishidoya1, Akihiro Ito1, Kazuhiko Orikasa1, Sadafumi Kawamura2, Tatsuo Tochigi2, Masaaki Kuwahara2, Takuya Yamanobe3, Yoshihiko Tomita3, Naoya Masumori4, Taiji Tsukamoto4, Daisuke Shibuya5 and Yoichi Arai1

1 Department of Urology, Tohoku University Graduate School of Medicine, Sendai
2 Department of Urology, Miyagi Cancer Center, Natori, Miyagi
3 Department of Urology, Yamagata University School of Medicine, Yamagata
4 Department of Urology, Sapporo Medical University School of Medicine, Sapporo
5 Miyagi-Taigan Kyokai, Sendai, Japan

For reprints and all correspondence: Shigeto Ishidoya, Department of Urology, Tohoku University Graduate School of Medicine, 1-1, Seiryo-machi Aoba-ku, Sendai 980-8574, Japan. E-mail: ishidoya{at}uro.med.tohoku.ac.jp

Received July 16, 2008; accepted September 10, 2008

Objective: No previous study has reported the numbers of prostate cancer (PC) patients existing among a normal Japanese population with prostate-specific antigen (PSA) < 4 ng/ml. The aim of this study was to elucidate the performance of %free PSA as a screening tool for a normal Japanese population with PSA of 2–4 ng/ml and to examine the characteristics of cancer detected using this criterion.

Methods: We conducted a prospective, multi-center study to evaluate the performance of %free PSA among a normal Japanese population. We decided on a %free PSA cutoff value of 12% according to the preliminary results. A total of 5548 consecutive screening volunteers aged 50–79 years were enrolled in the project. Men with total PSA > 4 ng/ml, or men with total PSA of 2–4 ng/ml and %free PSA of ≤12% were indicated to undergo 12 core biopsies.

Results: There were 826 (14.9%) men with PSA of 2–4 ng/ml. Among them, those with %free PSA of ≤12% numbered 100 (12.1%). Forty-nine out of 100 men (49%) received biopsy, and 16 PC patients were detected. Among 10 patients undergoing radical prostatectomy, seven were associated with extra-prostatic extension (pT3) or high-grade cancer (Gleason score ≥ 8).

Conclusions: We confirmed the ability of %free PSA and demonstrated that there are considerable numbers of PC patients among the normal Japanese population with PSA of 2–4 ng/ml. We ascertained that cancers detected in this study had a variety of tumor characteristics, including those of an aggressive nature.

Key Words: prostate cancer • screening • PSA • %free PSA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.